EDITOR'S DESK

  • The Debate On Standards In Biologics Development Heats Up
    The Debate On Standards In Biologics Development Heats Up

    Though it’s only natural to expect animated scientific discussion between the FDA and USP which have long been partners-in-science, I found myself caught off-guard by just how firmly the FDA has been putting its foot down and making its thoughts known on the role certain standards — in particular, USP monographs — should (or should not play) in biologics development.

FDA’s “Show Me The Data” A Recipe For Tailored Biosimilar Development?

In this first of what will be a two-part article, USP's Fouad Atouf highlights the challenges presented by the FDA’s newest guidance while remaining optimistic that the large amount of data recommended today will open doors to more efficient development in the (hopefully) near future.

Why We Should Celebrate The FDA’s Biosimilar Comparative Analytics Guidance

Despite the importance of the process the FDA is outlining in the guidance, I’ve surprisingly heard little chatter — positive or negative — about what the agency is now outlining and what this may mean for biosimilars and the biosimilar regulatory paradigm moving forward. Here are a couple of the biggest takeaways to note.

3 Countries To Watch In The MENA Region

Though there is a large handful of countries that, to date, don’t have biosimilar pathways established, a few countries have been slowly gearing up to be leaders in paving the way for biologics and biosimilars. In this article, I’ll discuss the potential of these three markets, as well as the business considerations Challand highlighted for companies considering entering the MENA region.

MENA: Biosimilar Market Challenges And Regulatory Considerations

Throughout her presentation, Challand gave us a good look at the current state of the biologics market in MENA and the ongoing educational and collaborative efforts that could help shape the markets in this region. She also shared several important considerations for regulators and biosimilar companies looking to expand their business to MENA.

More From Our Editors

GUEST COLUMNISTS

  • Does A Phase 1 Virtual Biopharma Company Need A cGMP Quality System?
    Does A Phase 1 Virtual Biopharma Company Need A cGMP Quality System?

    Virtual pharmaceutical/biotech companies often receive conflicting advice regarding the need to establish an internal cGMP quality system. Either they’re told “you need an extensive set of cGMP SOPs” or “you don’t need any cGMP SOPs at all.” Which advice is correct?

  • 4 Important Things To Consider Before Developing A Drug Delivery Device
    4 Important Things To Consider Before Developing A Drug Delivery Device

    This is Part 1 of a two-part article discussing important areas to consider when developing devices for combination products — and why they need to be addressed early in development.

  • 2019 U.S. State Policy Trends Impacting Pharma Manufacturers
    2019 U.S. State Policy Trends Impacting Pharma Manufacturers

    If the activity happening in state legislatures across the country heralds change at the federal level — and it likely does — pharmaceutical manufacturers ought to buckle their seatbelts.

  • Establishing And Maintaining A Treatment Network For Your Cell And Gene Therapy Product
    Establishing And Maintaining A Treatment Network For Your Cell And Gene Therapy Product

    Delivering cell and gene therapies is an expensive and highly complex process, and there are a number of critical metrics that manufacturers should consider when selecting treatment sites. Subsequent activities — preparing sites to receive and initiate therapy, and managing site training and ongoing certification — can be equally, if not more, challenging.

  • How To Prepare For An FDA Inspection
    How To Prepare For An FDA Inspection

    An FDA inspection is very different than an ISO certification or surveillance audit — too often, organizations “prepare” for scheduled ISO audits by playing catch-up on activities that have been neglected or otherwise overlooked. The catch-up strategy will be problematic for FDA inspections and will generally result in inspectional observations.

  • 3 Surefire Approaches To SOP Harmonization
    3 Surefire Approaches To SOP Harmonization

    We seem to be buried in standard operating procedures (SOPs). So how the heck are companies supposed to make the SOP mountain smaller through harmonization?

  • How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy
    How 2 Recent Court Cases Could Impact Follow-On Biologics Strategy

    As follow-on biologics litigation expands, and the FDA provides additional information on the approval process for follow-on biologics, industry and observers are gaining clarity on how the Biologics Price Competition and Innovation Act (BPCIA) functions in practice. This article provides insight into two recent developments that will impact strategic and economic considerations for biologics developers.

  • Next Steps For Serialization In The Pharma Supply Chain
    Next Steps For Serialization In The Pharma Supply Chain

    The industry has made unprecedented progress and addressed several challenges to ensure compliance with global pharmaceutical serialization and traceability requirements. While these requirements contain further regulatory milestones on the horizon, manufacturers, distributors, pharmacies, and other parties in the pharmaceutical supply chain must systematically adopt serialization in their normal business operations.

More From Our Guest Columnists

BIOPROCESSING WHITE PAPERS

More Bioprocessing White Papers

FREE CLEANING VALIDATION E-BOOK

Learn how to employ science-, risk-, and statistics-based approaches to cleaning and cleaning validation at your facility with this free, 100-page e-book, written by a global team of cleaning validation experts, pharmaceutical toxicologists, statisticians, and Six Sigma professionals.

LIFE SCIENCE INDUSTRY EVENTS

Lyophilization - An Introduction to the Scientific Principles August 27 - 27, 2019
1pm-2:30pm EST, Online Training
Straight to the Point: Reaching Clinical Stage Development with a CHOZN® Cell Line August 29, 2019
Time: 11:00 AM Eastern Daylight Time. Duration 1 Hour
BioProcess International September 9 - 12, 2019
Boston, MA
The Top Method Validation Mistakes – And How to Avoid Them September 9 - 9, 2019
1pm-2:30pm EDT, Online Training
More Industry Events

TRAINING COURSES

Lyophilization - An Introduction to the Scientific Principles August 27 - 27, 2019
1pm-2:30pm EST, Online Training
The Top Method Validation Mistakes – And How to Avoid Them September 9 - 9, 2019
1pm-2:30pm EDT, Online Training
Pediatric Clinical Trials: Special Considerations and Requirements September 13 - 13, 2019
1pm-2:30pm EDT, Online Training
How to Write SOPs That are GCP Compliant and Implementable September 17 - 17, 2019
1pm-2:30pm EDT, Online Training
More Upcoming Courses